@misc{10481/67945,
year = {2021},
month = {3},
url = {http://hdl.handle.net/10481/67945},
abstract = {Skin disease may be related with immunological disorders, external aggressions, or
genetic conditions. Injuries or cutaneous diseases such as wounds, burns, psoriasis,
and scleroderma among others are common pathologies in dermatology, and in some
cases, conventional treatments are ineffective. In recent years, advanced therapies
using human mesenchymal stem cells (hMSCs) from different sources has emerged
as a promising strategy for the treatment of many pathologies. Due to their properties;
regenerative, immunomodulatory and differentiation capacities, they could be applied
for the treatment of cutaneous diseases. In this review, a total of thirteen types of
hMSCs used as advanced therapy have been analyzed, considering the last 5 years
(2015–2020). The most investigated types were those isolated from umbilical cord
blood (hUCB-MSCs), adipose tissue (hAT-MSCs) and bone marrow (hBM-MSCs). The
most studied diseases were wounds and ulcers, burns and psoriasis. At preclinical
level, in vivo studies with mice and rats were the main animal models used, and a
wide range of types of hMSCs were used. Clinical studies analyzed revealed that cell
therapy by intravenous administration was the advanced therapy preferred except in
the case of wounds and burns where tissue engineering was also reported. Although
in most of the clinical trials reviewed results have not been posted yet, safety was high
and only local slight adverse events (mild nausea or abdominal pain) were reported.
In terms of effectiveness, it was difficult to compare the results due to the different
doses administered and variables measured, but in general, percentage of wound’s
size reduction was higher than 80% in wounds, Psoriasis Area and Severity Index
and Severity Scoring for Atopic Dermatitis were significantly reduced, for scleroderma,
parameters such as Modified Rodnan skin score (MRSC) or European Scleroderma
Study Group activity index reported an improvement of the disease and for hypertrophic
scars, Vancouver Scar Scale (VSS) score was decreased after applying these therapies.
On balance, hMSCs used for the treatment of cutaneous diseases is a promising
strategy, however, the different experimental designs and endpoints stablished in each
study, makes necessary more research to find the best way to treat each patient
and disease.},
organization = {Instituto de Salud Carlos III (European Regional Development Fund "A way to make Europe") 

PI13/02576
PI17/02083},
organization = {Andalusian Regional Government 

SAS PI-0458-2016
PIGE-0242-2019},
organization = {Instituto de Salud Carlos III (European Social Fund "Investing in your future") 

FI18/00269},
publisher = {Frontiers Media SA},
keywords = {Advanced therapies},
keywords = {Cell therapy},
keywords = {Dermatology},
keywords = {Mesenchymal Stem Cells},
keywords = {Skin diseases},
keywords = {Skin injuries},
keywords = {Stem cells},
keywords = {Tissue Engineering},
title = {Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases},
doi = {10.3389/fcell.2021.643125},
author = {Sierra Sánchez, Álvaro and Montero Vilchez, Trinidad and Quiñones Vico, María Isabel and Sánchez Diaz, Manuel and Arias Santiago, Salvador Antonio},
}